PPAR-γ and AMPK--advantageous targets for myocardial ischemia/reperfusion therapy
- PMID: 21536015
- DOI: 10.1016/j.bcp.2011.04.004
PPAR-γ and AMPK--advantageous targets for myocardial ischemia/reperfusion therapy
Abstract
Ischemic heart disease stands as the number one leading cause of death in the United States. Current interventions rely on the immediate restoration of blood flow to the ischemic area; however, this in turn may trigger a series of undesirable events that are further injurious to the myocardium, termed ischemia/reperfusion (I/R) injury. Therefore, there is a need for novel therapeutic strategies aimed at limiting the extent of myocardial injury. Yet, the molecular mechanisms responsible for I/R injury remain largely indefinable. Research efforts are currently investigating various signaling mechanisms to be used for potential targets limiting cardiac injury due to such cardiovascular events. In this review, we highlight two potential molecular targets, PPAR-γ and AMPK, which have been extensively reported to have various cardioprotective capabilities against I/R injury. Although functionally different, the pathways these proteins mediate seem to intersect and possibly act synergistically potentiating a cardioprotective response.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.Pharmacol Rev. 2007 Dec;59(4):418-58. doi: 10.1124/pr.107.06002. Epub 2007 Nov 29. Pharmacol Rev. 2007. PMID: 18048761 Review.
-
Activation of peroxisome-proliferator-activated receptors α and γ mediates remote ischemic preconditioning against myocardial infarction in vivo.Exp Biol Med (Maywood). 2011 Jan;236(1):113-22. doi: 10.1258/ebm.2010.010210. Epub 2010 Dec 16. Exp Biol Med (Maywood). 2011. PMID: 21163821
-
Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling.Diabetes. 2008 Mar;57(3):696-705. doi: 10.2337/db07-1098. Epub 2007 Dec 14. Diabetes. 2008. PMID: 18083782
-
A novel mechanism for cyclosporine: inhibition of myocardial ischemia and reperfusion injury in a heterotopic rabbit heart transplant model.J Heart Lung Transplant. 1996 Sep;15(9):936-47. J Heart Lung Transplant. 1996. PMID: 8889990
-
[Mechanisms of myocardial cell protection from ischemia/reperfusion injury and potential clinical implications].G Ital Cardiol (Rome). 2009 Jan;10(1):28-36. G Ital Cardiol (Rome). 2009. PMID: 19292017 Review. Italian.
Cited by
-
Nuciferine improves cardiac function in mice subjected to myocardial ischemia/reperfusion injury by upregulating PPAR-γ.Heliyon. 2023 Feb 11;9(2):e13630. doi: 10.1016/j.heliyon.2023.e13630. eCollection 2023 Feb. Heliyon. 2023. PMID: 36865453 Free PMC article.
-
Sulfide-modified nanoscale zero-valent iron as a novel therapeutic remedy for septic myocardial injury.J Adv Res. 2024 Jan;55:145-158. doi: 10.1016/j.jare.2023.02.008. Epub 2023 Feb 17. J Adv Res. 2024. PMID: 36801383 Free PMC article.
-
Role of AMPK in Myocardial Ischemia-Reperfusion Injury-Induced Cell Death in the Presence and Absence of Diabetes.Oxid Med Cell Longev. 2022 Oct 11;2022:7346699. doi: 10.1155/2022/7346699. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 36267813 Free PMC article. Review.
-
PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery.J Clin Med. 2022 Jun 23;11(13):3638. doi: 10.3390/jcm11133638. J Clin Med. 2022. PMID: 35806921 Free PMC article. Review.
-
Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases.Cell Biosci. 2022 Mar 12;12(1):30. doi: 10.1186/s13578-022-00763-0. Cell Biosci. 2022. PMID: 35279210 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
